In: Obesity Surgery, 2015, vol. 25, no. 11, p. 2054-2060
|
In: European Radiology, 2009, vol. 19, no. 6, p. 1311-1315
|
In: Intensive Care Medicine, 2004, vol. 30, no. 5, p. 817-821
|
In: Journal of Clinical Monitoring and Computing, 2008, vol. 22, no. 3, p. 183-188
|
In: Journal of Clinical Monitoring and Computing, 2007, vol. 21, no. 3, p. 147-153
|
In: Intensive Care Medicine, 2006, vol. 32, no. 6, p. 919-922
|
In: European Heart Journal, 2006, vol. 27, no. 13, p. 1558-1564
|
In: European Journal of Cardio-Thoracic Surgery, 2008, vol. 34, no. 3, p. 653-660
|
In: European Heart Journal, 2013, vol. 34, no. 46, p. 3557-3562
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|